Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.

被引：6
|
作者：
Klempner, Samuel J.
Lee, Keun-Wook
Metges, Jean-Philippe
Catenacci, Daniel V. T.
Loupakis, Fotios
Ilson, David H.
Shah, Manish A.
Shitara, Kohei
Arozullah, Ahsan
Park, Jung Wook
Raizer, Jeffrey J.
Bang, Yung-Jue
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea
[3] Hop Morvan, Ctr Hosp Reg Univ Brest, Brest, France
[4] Univ Chicago, Gastrointestinal Oncol Program, Chicago, IL 60637 USA
[5] Univ Azienda Osped Univ Pisana, Pisa, Italy
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Weill Cornell Med Coll, New York, NY USA
[8] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[9] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[10] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16063
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).
    Lee, Keun-Wook
    Klempner, Samuel J.
    Yang, Jianning
    Desai, Amit
    Yamada, Akihiro
    Ueno, Yoko
    Wojtkowski, Tomasz
    Park, Jung Wook
    Pavese, Janet
    Loupakis, Fotios
    Bang, Yung-Jue
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-ILUSTRO Cohort 3.
    Klempner, Samuel J.
    Ajani, Jaffer A.
    Al-Batran, Salah-Eddin
    Bang, Yung-Jue
    Catenacci, Daniel V. T.
    Enzinger, Peter C.
    Ilson, David H.
    Kim, Sunnie
    Lordick, Florian
    Shah, Manish A.
    Shitara, Kohei
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Van Cutsem, Eric
    Xu Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [3] ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
    Klempner, Samuel J.
    Lee, Keun-Wook
    Shitara, Kohei
    Metges, Jean-Phillippe
    Lonardi, Sara
    Ilson, David H.
    Fazio, Nicola
    Kim, Tae Yong
    Bai, Li-Yuan
    Moran, Diarmuid
    Yang, Jianning
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Bang, Yung-Jue
    Shah, Manish A.
    CLINICAL CANCER RESEARCH, 2023, 29 (19) : 3882 - 3891
  • [4] Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas
    Shitara, Kohei
    Yamaguchi, Kensei
    Shoji, Hirokazu
    Matsangou, Maria
    Bhattacharya, Pranob P.
    Park, Jung Wook
    Klempner, Samuel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] SPOTLIGHT: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Lordick, F.
    Shitara, K.
    Al-Batran, S. -E
    Bang, Y. -J
    Catenacci, D.
    Enzinger, P.
    Ilson, D.
    Kim, S.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R. -H
    Arozullah, A.
    Park, J. W.
    Ajani, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 218 - 218
  • [6] SPOTLIGHT: Phase III study of zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line Claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Shitara, K.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P. C.
    Ilson, D. H.
    Kim, S.
    Lordick, F.
    Shah, M. A.
    van Cutsem, E.
    Xu, R-H.
    Arozullah, A.
    Park, J. W.
    Ajani, J. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1317 - S1317
  • [7] GLOW: Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin18.2./HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Xu, R-H.
    Ajani, J. A.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P. C.
    Ilson, D. H.
    Kim, S.
    Lordick, F.
    Shitara, K.
    van Cutsem, E.
    Arozullah, A.
    Park, J. W.
    Shah, M. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1315 - S1316
  • [8] SPOTLIGHT: Comparison of zolbetuximab or placebo+mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
    Yamaguchi, K.
    Shitara, K.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P.
    Ilson, D.
    Kim, S.
    Lordick, F.
    Shah, M.
    Van Cutsem, E.
    Xu, R-H.
    Arozullah, A.
    Park, J. Wook
    Ajani, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] GLOW: Zolbetuximab plus CAPOX compared with placebo plus CAPOX as first-line treatment for patients with Claudin18.2+/HER2-Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
    Xu, R-H.
    Dongsheng, Z.
    Ajani, J.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P.
    Ilson, D.
    Kim, S.
    Lordick, F.
    Shitara, K.
    Van Cutsem, E.
    Arozullah, A.
    Park, J. Wook
    Shah, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
    Huang, Yufan
    You, Maojin
    Wu, Qundan
    Chen, Ruijia
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345